Antiasthma Drugs: β₂-Adrenoceptor Agonists

β2-adrenoceptor agonists target β2-receptors on bronchial smooth muscle cells, inducing muscle relaxation and dilating airways. This action alleviates wheezing, shortness of breath, and chest tightness. The medications work by stimulating these receptors to facilitate easier breathing and restore normal airflow during asthma episodes.

Short-acting β2-agonists (SABAs) like albuterol and terbutaline provide immediate relief during acute asthma episodes by rapidly relaxing airway muscles. Long-acting β2-agonists (LABAs) such as salmeterol and formoterol sustain bronchodilation over extended periods, serving as preventive measures for chronic bronchial conditions to maintain open airways.

Metered-dose inhalers and nebulizers deliver β2-agonists directly to the respiratory tract, ensuring rapid medication delivery to target airways. This direct administration maximizes therapeutic effectiveness while minimizing systemic exposure, allowing patients to experience faster symptom relief with lower overall drug exposure.

The most common adverse effect is tremor, resulting from β2-receptor stimulation in skeletal muscles. Other potential side effects include tachycardia (rapid heart rate) and cardiac dysrhythmias (irregular heart rhythms) from β2-receptor stimulation in the heart. These systemic effects occur because β2-adrenoceptors are present throughout the body, not just in airways.

β2-agonists are pivotal bronchodilators in asthma management, with SABAs providing acute symptom relief and LABAs offering chronic prevention. They work alongside other antiasthma drugs including inhaled corticosteroids and glucocorticoids to comprehensively control airway inflammation and constriction, requiring medical supervision to monitor effectiveness and adverse effects.

SABAs rapidly penetrate airways and quickly relax bronchial muscles during acute episodes, providing immediate relief. LABAs maintain sustained bronchodilation through prolonged receptor stimulation, preventing airway constriction before it occurs. This dual mechanism—immediate versus sustained action—allows β2-agonists to address both emergency symptoms and long-term disease control.

When β2-agonists relax bronchial smooth muscle, the airways dilate, reducing resistance to airflow and restoring normal breathing patterns. This bronchial muscle relaxation directly counteracts the airway constriction characteristic of asthma, allowing air to flow freely through the respiratory tract and eliminating symptoms like wheezing and breathlessness.